227 related articles for article (PubMed ID: 26401581)
21. Transgenic Wuzhishan minipigs designed to express a dominant-negative porcine growth hormone receptor display small stature and a perturbed insulin/IGF-1 pathway.
Li F; Li Y; Liu H; Zhang X; Liu C; Tian K; Bolund L; Dou H; Yang W; Yang H; Staunstrup NH; Du Y
Transgenic Res; 2015 Dec; 24(6):1029-42. PubMed ID: 26510874
[TBL] [Abstract][Full Text] [Related]
22. NREM sleep architecture and relation to GH/IGF-1 axis in Laron syndrome.
Verrillo E; Bizzarri C; Cappa M; Bruni O; Pavone M; Cutrera R
Horm Res Paediatr; 2010; 73(5):414-9. PubMed ID: 20389115
[TBL] [Abstract][Full Text] [Related]
23. Effects of GH/IGF-I Axis on Retinal Vascular Morphology: Retinal Vascular Characteristics in a Clinical Setting with Severe IGF-I Deficiency.
Sekeroglu HT; Kadayıfcılar S; Kasım B; Arslan U; Ozon A
Ophthalmic Genet; 2016; 37(1):53-8. PubMed ID: 25078475
[TBL] [Abstract][Full Text] [Related]
24. Differential expression of IGFBPs in Laron syndrome-derived lymphoblastoid cell lines: Potential correlation with reduced cancer incidence.
Somri L; Sarfstein R; Lapkina-Gendler L; Nagaraj K; Laron Z; Bach LA; Werner H
Growth Horm IGF Res; 2018 Apr; 39():6-12. PubMed ID: 29208357
[TBL] [Abstract][Full Text] [Related]
25. Clinical, Endocrine, and Molecular Genetic Analysis of a Large Cohort of Saudi Arabian Patients with Laron Syndrome.
Al-Ashwal AA; Al-Sagheir A; Ramzan K; Al-Owain M; Allam R; Qari A; Al-Numair NS; Imtiaz F
Horm Res Paediatr; 2017; 88(2):119-126. PubMed ID: 28743110
[TBL] [Abstract][Full Text] [Related]
26. Genetic disorders in the growth hormone - insulin-like growth factor-I axis.
Walenkamp MJ; Wit JM
Horm Res; 2006; 66(5):221-30. PubMed ID: 16917171
[TBL] [Abstract][Full Text] [Related]
27. Obese adults with primary growth hormone resistance (Laron Syndrome) have normal endothelial function.
Shechter M; Ginsberg S; Scheinowitz M; Feinberg MS; Laron Z
Growth Horm IGF Res; 2007 Apr; 17(2):165-70. PubMed ID: 17320443
[TBL] [Abstract][Full Text] [Related]
28. Insights from the clinical phenotype of subjects with Laron syndrome in Ecuador.
Guevara-Aguirre J; Bautista C; Torres C; Peña G; Guevara C; Palacios C; Guevara A; Gavilanes AWD
Rev Endocr Metab Disord; 2021 Mar; 22(1):59-70. PubMed ID: 33047268
[TBL] [Abstract][Full Text] [Related]
29. Long-term IGF-I treatment of children with Laron syndrome increases adiposity.
Laron Z; Ginsberg S; Lilos P; Arbiv M; Vaisman N
Growth Horm IGF Res; 2006 Feb; 16(1):61-4. PubMed ID: 16442822
[TBL] [Abstract][Full Text] [Related]
30. Reporting a novel growth hormone receptor gene variant in an Iranian consanguineous pedigree with Laron syndrome: a case report.
Bitarafan F; Khodaeian M; Garrousi F; Khalesi R; Ghazi Nader D; Karimi B; Alibakhshi R; Garshasbi M
BMC Endocr Disord; 2023 Jul; 23(1):155. PubMed ID: 37474955
[TBL] [Abstract][Full Text] [Related]
31. Identification of signaling pathways associated with cancer protection in Laron syndrome.
Lapkina-Gendler L; Rotem I; Pasmanik-Chor M; Gurwitz D; Sarfstein R; Laron Z; Werner H
Endocr Relat Cancer; 2016 May; 23(5):399-410. PubMed ID: 27090428
[TBL] [Abstract][Full Text] [Related]
32. Insulin-like growth factor-I raises serum procollagen levels in children and adults with Laron syndrome.
Klinger B; Jensen LT; Silbergeld A; Laron Z
Clin Endocrinol (Oxf); 1996 Oct; 45(4):423-9. PubMed ID: 8959080
[TBL] [Abstract][Full Text] [Related]
33. Biphasic response of subscapular skinfold thickness to hGH or IGF-1 administration to patients with congenital IGHD, congenital MPHD and Laron syndrome.
Bisker-Kassif O; Kauli R; Lilos P; Laron Z
Obes Res Clin Pract; 2014; 8(1):e55-62. PubMed ID: 24548577
[TBL] [Abstract][Full Text] [Related]
34. Primary GH insensitivity '(Laron syndrome) caused by a novel 4 kb deletion encompassing exon 5 of the GH receptor gene: effect of intermittent long-term treatment with recombinant human IGF-I.
Besson A; Salemi S; Eblé A; Joncourt F; Gallati S; Jorge AA; Mullis PE
Eur J Endocrinol; 2004 May; 150(5):635-42. PubMed ID: 15132718
[TBL] [Abstract][Full Text] [Related]
35. Laron Syndrome Research Paves the Way for New Insights in Oncological Investigation.
Werner H; Sarfstein R; Nagaraj K; Laron Z
Cells; 2020 Nov; 9(11):. PubMed ID: 33182502
[TBL] [Abstract][Full Text] [Related]
36. Diabetes mellitus with Laron syndrome: case report.
Agladıoglu SY; Cetınkaya S; Savas Erdeve S; Onder A; Kendırcı HN; Bas VN; Aycan Z
J Pediatr Endocrinol Metab; 2013; 26(9-10):955-8. PubMed ID: 23729552
[TBL] [Abstract][Full Text] [Related]
37. Phenotypes, investigation and treatment of primary IGF-1 deficiency.
Savage MO
Endocr Dev; 2013; 24():138-49. PubMed ID: 23392102
[TBL] [Abstract][Full Text] [Related]
38. Growth hormone insensitivity syndrome caused by a heterozygous GHR mutation: phenotypic variability owing to moderation by nonsense-mediated decay.
Gorbenko del Blanco D; de Graaff LC; Visser TJ; Hokken-Koelega AC
Clin Endocrinol (Oxf); 2012 May; 76(5):706-12. PubMed ID: 22117696
[TBL] [Abstract][Full Text] [Related]
39. Insulin-like growth factor-I deficiency in children with growth hormone insensitivity: current and future treatment options.
Kemp SF
BioDrugs; 2009; 23(3):155-63. PubMed ID: 19627167
[TBL] [Abstract][Full Text] [Related]
40. The GH-IGF1 axis and longevity. The paradigm of IGF1 deficiency.
Laron Z
Hormones (Athens); 2008; 7(1):24-7. PubMed ID: 18359741
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
